Cargando…
Autoinhibition of Bcr-Abl through Its SH3 Domain
Bcr-Abl is a dysregulated tyrosine kinase whose mechanism of activation is unclear. Here, we demonstrate that, like c-Abl, Bcr-Abl is negatively regulated through its SH3 domain. Kinase activity, transformation, and leukemogenesis by Bcr-Abl are greatly impaired by mutations of the Bcr coiled-coil d...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press. Published by Elsevier Inc.
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128750/ https://www.ncbi.nlm.nih.gov/pubmed/12887890 http://dx.doi.org/10.1016/S1097-2765(03)00274-0 |
_version_ | 1783516633806929920 |
---|---|
author | Smith, Kristen M. Yacobi, Rinat Van Etten, Richard A. |
author_facet | Smith, Kristen M. Yacobi, Rinat Van Etten, Richard A. |
author_sort | Smith, Kristen M. |
collection | PubMed |
description | Bcr-Abl is a dysregulated tyrosine kinase whose mechanism of activation is unclear. Here, we demonstrate that, like c-Abl, Bcr-Abl is negatively regulated through its SH3 domain. Kinase activity, transformation, and leukemogenesis by Bcr-Abl are greatly impaired by mutations of the Bcr coiled-coil domain that disrupt oligomerization, but restored by an SH3 point mutation that blocks ligand binding or a complementary mutation at the intramolecular SH3 binding site defined in c-Abl. Phosphorylation of tyrosines in the activation loop of the catalytic domain and the linker between the SH2 and catalytic domains (SH2-CD linker) is dependent on oligomerization and required for leukemogenesis. These results suggest that Bcr-Abl has a monomeric, unphosphorylated state with the SH3 domain engaged intramolecularly to Pro1124 in the SH2-CD linker, the form that is sensitive to the inhibitor imatinib (STI-571). The sole function of the coiled-coil domain is to disrupt the autoinhibited conformation through oligomerization and intermolecular autophosphorylation. |
format | Online Article Text |
id | pubmed-7128750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Cell Press. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71287502020-04-08 Autoinhibition of Bcr-Abl through Its SH3 Domain Smith, Kristen M. Yacobi, Rinat Van Etten, Richard A. Mol Cell Article Bcr-Abl is a dysregulated tyrosine kinase whose mechanism of activation is unclear. Here, we demonstrate that, like c-Abl, Bcr-Abl is negatively regulated through its SH3 domain. Kinase activity, transformation, and leukemogenesis by Bcr-Abl are greatly impaired by mutations of the Bcr coiled-coil domain that disrupt oligomerization, but restored by an SH3 point mutation that blocks ligand binding or a complementary mutation at the intramolecular SH3 binding site defined in c-Abl. Phosphorylation of tyrosines in the activation loop of the catalytic domain and the linker between the SH2 and catalytic domains (SH2-CD linker) is dependent on oligomerization and required for leukemogenesis. These results suggest that Bcr-Abl has a monomeric, unphosphorylated state with the SH3 domain engaged intramolecularly to Pro1124 in the SH2-CD linker, the form that is sensitive to the inhibitor imatinib (STI-571). The sole function of the coiled-coil domain is to disrupt the autoinhibited conformation through oligomerization and intermolecular autophosphorylation. Cell Press. Published by Elsevier Inc. 2003-07 2003-07-29 /pmc/articles/PMC7128750/ /pubmed/12887890 http://dx.doi.org/10.1016/S1097-2765(03)00274-0 Text en Copyright © 2003 Cell Press. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Smith, Kristen M. Yacobi, Rinat Van Etten, Richard A. Autoinhibition of Bcr-Abl through Its SH3 Domain |
title | Autoinhibition of Bcr-Abl through Its SH3 Domain |
title_full | Autoinhibition of Bcr-Abl through Its SH3 Domain |
title_fullStr | Autoinhibition of Bcr-Abl through Its SH3 Domain |
title_full_unstemmed | Autoinhibition of Bcr-Abl through Its SH3 Domain |
title_short | Autoinhibition of Bcr-Abl through Its SH3 Domain |
title_sort | autoinhibition of bcr-abl through its sh3 domain |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128750/ https://www.ncbi.nlm.nih.gov/pubmed/12887890 http://dx.doi.org/10.1016/S1097-2765(03)00274-0 |
work_keys_str_mv | AT smithkristenm autoinhibitionofbcrablthroughitssh3domain AT yacobirinat autoinhibitionofbcrablthroughitssh3domain AT vanettenricharda autoinhibitionofbcrablthroughitssh3domain |